ISB News

New Research Unveils Effective STEM Program Models for High School Students from Historically Marginalized Communities

An ISB-led study has unveiled important insights and actionable protocols into providing equitable STEM experiences for high school students from historically marginalized communities. The research highlights the transformative power of informal STEM learning in addressing societal challenges and the ease with which many organizations could provide these important opportunities.

Common Immune Response Protective Across Many Diseases

Combined, infection, autoimmunity and cancer account for 40 percent of deaths worldwide and represent major global health challenges. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases. Their findings offer promising avenues for exploring multi-disease therapeutic strategies.

Autoimmune Disease and Pregnancy: ISB Study Challenges Prevailing Wisdom, Unveils Nuances

An ISB-led study showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease. The findings reinforce that there isn’t a one-size-fits-all approach, and provides important new avenues for further investigation.

Breakthrough T Cell Discovery Has Huge Potential for Engineering Custom Immune Responses

In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.

ISB Associate Professor Dr. Sean Gibbons

‘1 in 1,000:’ Dr. Sean Gibbons Named Highly Cited Researcher for 2023

ISB Associate Professor Dr. Sean Gibbons was named a Highly Cited Researcher for 2023. It is the second consecutive year Gibbons has earned the distinction. The Highly Cited Research list is generated annually by Clarivate, which says: “Of the world’s population of scientists and social scientists, Highly Cited Researchers are 1 in 1,000.”

ISB Researchers Find a Chink in the Armor of Tuberculosis Pathogen

By using a computer model to understand the adaptions of Mycobacterium tuberculosis (Mtb), the pathogen that causes tuberculosis, researchers at ISB have identified a network within Mtb that allows it to tolerate and resist drug therapies. This work is published in Cell Reports.

Lifestyle coaching improves cognitive decline in Alzheimer's disease trial.

Personalized Coaching Decreases Cognitive Decline in Early-Stage Alzheimer’s Disease Patients

Supplementing the standard of treatment for Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of treatment alone, according to an ISB-led two-year study. The results were published in the Journal of Alzheimer’s Disease.

Drs. Jennifer Hadlock and Samantha Piekos

COVID-19 Vaccines and Boosters Associated with Lower Rates of Stillbirth, New ISB Study Shows

Pregnant people who are vaccinated are less likely to contract COVID-19 than unvaccinated pregnant people, and those vaccinated and boosted are less likely to get COVID than those who are vaccinated only, according to the first-ever large study of boosters and pregnancy.

Dr. Hadlock

Dr. Jennifer Hadlock Promoted to Associate Professor

Dr. Jennifer Hadlock – an expert in machine learning, immune-mediated inflammatory disease, and maternal/fetal health – has been promoted to associate professor. The Hadlock Lab is an interdisciplinary team that aims to accelerate translational research by integrating clinical data into systems biology at scale.

Building a Better BMI

ISB researchers have constructed biological body mass index (BMI) measures that offer a more accurate representation of metabolic health and are more varied, informative and actionable than the traditional, long-used BMI equation. The work was published in the journal Nature Medicine. 

AmeriCorps Member Sara Calder Joins ISB as Systems Health and STEM Coordinator

Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.

In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.

The Gut Microbiome’s Supersized Role In Shaping Our Metabolome

ISB researchers have shown which blood metabolites are associated with the gut microbiome, genetics, or the interplay between both. Their findings, published in the journal Nature Metabolism, have promising implications for guiding targeted therapies designed to alter the composition of the blood metabolome to improve human health.

ISB President Dr. Jim Heath

ISB Leading NCI Comprehensive Cancer Center to Study Sequential Targeted Inhibitors and Immunotherapies

The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.

Gut Microbiome Composition Predictive of Patient Response to Statins

New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.

Risk Factors for Severe COVID-19 in Hospitalized Adults Differ by Age

A just-published study provides new information about which hospitalized COVID-19 patients are most likely to need mechanical ventilation or to die. The ISB-led work shows that vital signs and lab results at the time of hospital admission are the most accurate predictors of disease severity, more so than comorbidities and demographics.

Understanding, Preventing and Treating Long-Term Effects of COVID: RECOVER Study Enrolling Patients from Pacific Northwest

As part of a massive nationwide effort, ISB is leading a multi-site consortium for the NIH RECOVER (Researching COVID to Enhance Recovery) Initiative. The Pacific Northwest consortium is made up of ISB, Providence, Swedish, and University of Washington School of Medicine.

Jim Heath AACR Academy Fellow

Dr. Jim Heath Named Fellow of AACR Academy Class of 2022

Dr. Jim Heath was announced as a newly elected Fellow of the American Academy for Cancer Research (AACR) Academy Class of 2022. “I am honored and humbled to be recognized as part of this renowned group of researchers who have done so much to move our understanding of cancer forward,” Heath said.